Research Article| Volume 46, ISSUE 5, P410-415, 1993

The use of FK506 and skin allografting for the treatment of severe burns in an animal model

      This paper is only available as a PDF. To read, Please Download here.


      A 30% burn injury was found highly immunosuppressive in mice by means of twoin vivo measurements of cell-mediated immunity, and this immunosuppression could be prevented by early excision and grafting. FK506, a new immunosuppressive agent, was given at different doses for 12 days after early excision and grafting following burn and all doses prolonged the acceptance time of allografts from 14 to 20 days. Allograft rejection was not seen when animals were on the drug. Higher doses prolonged the rejection more, even after the cessation of the drug, and they caused some degree of immunodepression. Immunosuppressive treatment with FK506 when used following burn injury affected cell-mediated immunity minimally to moderately when compared to burned control groups.


        • Hansbrough JF
        Current status of skin replacement for coverage of extensive burn wounds.
        J Trauma. 1990; 30: S155-S162
        • Phipps AR
        • Clarke JA
        The use of intermingled autograft and parental allograft skin in the treatment of major burns in children.
        Br J Plast Surg. 1991; 44: 608-611
        • Tompkins RG
        • Burke JF
        Progress in burn treatment and the use of artificial skin.
        World J Surg. 1990; 14: 819-824
        • Krob MJ
        • Shelby J
        Immunosuppressive effects of burn injury and nonspecific blood transfusion.
        J Trauma. 1986; 26: 40-43
        • Ninnemann JL
        • Fisher JC
        • Frank HA
        Prolonged survival of human skin allografts following thermal injury.
        Trans. 1978; 25: 69-72
        • Batchelor JR
        • Hackett M
        HL-A matching in treatment of burned patients with skin allografts.
        Lancet. 1970; 2: 581-583
        • Achauer BM
        • Hewitt CW
        • Black KS
        • Philosophe B
        • Linfesty RL
        • Furnas DW
        Cyclosporine prolongs skin allografts in a rat burn model.
        in: Transplant Proc. 15. 1983: 3073-3076 (suppl 1)
        • Achauer BM
        • Hewitt CW
        • Black KS
        • et al.
        Long-term skin allograft survival after short-term cyclosporine treatment in a patient with massive burns.
        Lancet. 1986; 1: 14-15
        • Frame JD
        Short-term cyclosporin and meshed allografts in burns.
        Lancet. 1987; 1: 154-155
        • Frame JD
        • Goodacre TEE
        • Morgan BDG
        The fate of meshed allograft skin in burned patients using cyclosporin immunosuppression.
        Br J Plast Surg. 1989; 42: 27-34
        • Sakabu SA
        • Hansbrough JF
        • Cooper ML
        • Greenleaf G
        Cyclosporine A for prolonging allograft survival in patients with massive burns.
        J Burn Care Rehabil. 1990; 11: 410-418
        • Thomson AW
        FK506—How much potential?.
        Immunology Today. 1989; 10: 6-9
        • Todo S
        • Ieda Y
        • Demetris AJ
        • et al.
        Immunosuppression of canine, monkey, and baboon allografts by FK506: with special reference to synergism with other drugs and to tolerance induction.
        Surgery. 1988; 104: 239-249
        • Arai K
        • Hotokebuchi T
        • Miyahara H
        • et al.
        Limb allografts in rats immunosuppressed with FK506.
        Trans. 1989; 48: 782-786
        • Inamura N
        • Nakahara K
        • Kino T
        • et al.
        Prolongation of skin allograft survival in rats by immunosuppressive agent, FK506.
        Trans. 1988; 45: 206-209
        • Thomson AW
        FK506 enters the clinic.
        Immunology Today. 1990; 11: 35-36
        • Lagodzinski Z
        • Gorski A
        • Wasik M
        Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice.
        Immunology. 1990; 71: 148-150
        • Walker HL
        • Mason AD
        A standard animal burn.
        J Trauma. 1968; 8: 1049-1051
        • Hansbrough JF
        • Peterson V
        • Kortz E
        • Piacentine J
        Postburn immunosuppression in an animal model: monocyte dys-function induced by burned tissue.
        Surgery. 1983; 93: 415-423
        • Hansbrough JF
        • Peterson V
        • Zapata-Sirvent R
        • Claman HN
        Postburn immunosuppression in animal model. II. Restoration of cell-mediated immunity by immunomodulating drugs.
        Surgery. 1984; 95: 290-295
        • Shelby J
        • Merrel S
        In vivo monitoring of postburn immune response.
        J Trauma. 1987; 27: 213-216
        • Echinard CE
        • Sajdel-Sulkowska E
        • Burke PA
        • Burke JF
        The beneficial effect of early excision on clinical response and thymic activity after burn injury.
        J Trauma. 1982; 22: 560-565
        • Tchervenkov JI
        • Epstein MD
        • Silberstein EB
        • Alexander JW
        Early burn would excision and skin grafting postburn trauma restores in vivo neutrophil delivery to inflammatory lesions.
        Arch Surg. 1988; 123: 1477-1481
        • Black KS
        • Hewitt CW
        • Smelser S
        • Yearsley S
        • Bazzo DE
        • Achauer BM
        Cyclosporine and skin allografts for the treatment of thermal injury. II. Development of an experimental massive third degree burn model demonstrating extensive graft survival.
        Trans. 1988; 45: 13-16
        • Hewitt CW
        • Black KS
        • Aguinaldo AMA
        • Achauer BM
        • Howard EB
        Cyclosporine and skin allografts for the treatment of thermal injury. I. Extensive graft survival with low-level long-term administration and pronlongation in a rat burn model.
        Trans. 1988; 45: 8-12
        • Hewitt CW
        • Black KS
        Comparative studies of FK506 with Cyclosporine.
        Trans. 1988; 46: 482
        • Kuroki H
        • Ishida O
        • Daisaku H
        • et al.
        Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK506 or cyclosporine.
        in: Transplant Proc. 23. 1991: 516-520
        • Starzl T
        • Todo S
        • Fung J
        • Demetris AJ
        • Venkataramman R
        • Jain A
        FK506 for liver, kidney, and pancreas transplantation.
        Lancet. 1989; 28: 1000-1004
        • Ochiaj T
        • Nakajima K
        • Suzuki T
        • et al.
        Effect of a new immunosuppressive agent, FK506, on hetorotopic cardiac allotransplantation in the rat.
        in: Transplant Proc. 19. 1987: 1284-1286
        • Miyagawa S
        • Stepkowski SM
        • Kahan BD
        Mechanism of unresponsiveness in rats induced by a short course of FK506 or CyA.
        in: Transplant Proc. 23. 1991: 334-335
        • Kuroki H
        • Bean M
        • Ikuta Y
        • Burges E
        Enhancement of rat skin and limb allograft survival by FK506 and DST.
        in: Presented at First International Congress of FK506, Pittsburgh, Pennsylvania, 21–24 August1991 (ET131)
        • Wada H
        • Monden M
        • Gotoh M
        • et al.
        An attempt to induce tolerance to skin grafts in congenic mice with FK506.
        in: Presented at First International Congress of FK506, Pittsburgh, Pennsylvania, 21–24 August1991 (ET129)
        • Kang K
        • Wen-Zeng W
        Effect of FK506 on skin allografts in mice.
        in: Presented at First International Congress of FK506, Pittsburgh, Pennsylvania, 21–24 August1991 (ET130)